Xoma | XOMA - Gross Profit On Sales

Stock Price
26.61
Daily Change
0.23 0.87%
Monthly
8.75%
Yearly
28.36%
Q1 Forecast
25.58

Xoma reported 992K in Gross Profit on Sales for its fiscal quarter ending in June of 2024.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Agenus USD 23.93M 2.79M Mar/2025
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
Ardelyx USD 106.35M 23.51M Sep/2025
aTyr Pharma USD 190K 15.57M Sep/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Celldex Therapeutics USD 121K 609K Dec/2025
Curis USD -7.72M 140K Jun/2024
Eli Lilly USD 14.59B 1.48B Sep/2025
Incyte USD 1.39B 118.68M Dec/2025
MacroGenics USD 61.25M 88.71M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Novartis USD 10.82B 694M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Prothena USD 2.42M 38.52M Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Xoma 992K 846K Jun/2024